AMGN · News · 20261001N

Guidance and Outlook

AMGEN INC · 2026-10-01 · Importance 10 · Surprise 6

Amgen maintained its full-year adjusted earnings-per-share guidance in connection with its second-quarter 2026 results. The digest did not disclose the guidance range or any numerical revision. Maintaining the guidance indicates no reported change to the company’s previously stated adjusted EPS outlook as of September 2026.

Key facts

• Amgen's next earnings date was scheduled for November 2, 2026. source
• Insiders have sold $29.3 million worth of Amgen shares over the past year without any purchases. source
• Amgen maintained its full-year adjusted earnings-per-share guidance. source
• GuruFocus's GF Value assessment indicates Amgen is overvalued by 10.8% compared to an estimated fair value of $367.70. source